Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

Amicus Therapeutics, Inc. (FOLD) reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus Estimate of a loss of 6 cents. The company had reported a loss of 17 cents per share in the year-ago quarter.The year-over-year improvement can be attributed to higher revenues of Galafold (migalastat) and the successful ongoing commercial launch of the newly approved Pombiliti + Opfolda.Revenues in the fourth quarter totaled $115.1 million, up 31% year over year on a reported basi ...